The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
Development of a Novel Long-Acting Antidiabetic FGF21 Mimetic by Targeted Conjugation to a Scaffold Antibody
Abstract
Fibroblast growth factor (FGF)21 improves insulin sensitivity, reduces body weight, and reverses hepatic steatosis in preclinical species. We generated long-acting FGF21 mimetics by site-specific conjugation of the protein to a scaffold antibody. Linking FGF21 through the C terminus decreased bioactivity, whereas bioactivity was maintained by linkage to selected internal positions. In mice, these CovX-Bodies retain efficacy while increasing half-life up to 70-fold compared with wild-type FGF21. A preferred midlinked CovX-Body, CVX-343, demonstrated enhanced in vivo stability in preclinical species, and a single injection improved glucose tolerance for 6 days in ob/ob mice. In diet-induced obese mice, weekly doses of CVX-343 reduced body weight, blood glucose, and lipids levels. In db/db mice, CVX-343 increased glucose tolerance, pancreatic β-cell mass, and proliferation. CVX-343, created by linkage of the CovX scaffold antibody to the engineered residue A129C of FGF21 protein, demonstrated superior preclinical pharmacodynamics by extending serum half-life of FGF21 while preserving full therapeutic functionality.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, disrupting leptin signaling using ob/ob or db/db mice abrogates the beneficial effects of FGF21 in lowering body weight in response to extended FGF21 administration (3, 45, 51, 67, 139).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [51]
In the citing paper
“The half-life of FGF21 is approximately 0.4–2 hours, depending on the species and method of delivery (51, 65, 142).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [51]
Citations
Cites
FGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125
The FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945
Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495
FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis
Fisher, F. M., Kleiner, S., Douris, N., Fox, E. C., Mepani, R. J., Verdeguer, F., Wu, J., Kharitonenkov, A., Flier, J. S., Maratos-Flier, E., et al. (2012) · Genes & Development · doi:10.1101/gad.177857.111 · Cited by 1,478 · cited 3×
“FGF21 has also been shown to promote browning of white adipose tissues through regulating PPARg coactivator-1a (PGC-1a) (Fisher et al., 2012) and promote thermogenic activation in neonatal brown fat and primary brown adipocytes (Hondares et al., 2010).”
BackgroundXu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R. A., et al. (2009) · Diabetes · doi:10.2337/db08-0392 · Cited by 1,151
Fibroblast Growth Factor 21 Corrects Obesity in Mice
Coskun, T., Bina, H. A., Schneider, M. A., Dunbar, J. D., Hu, C. C., Chen, Y., Moller, D. E., & Kharitonenkov, A. (2008) · Endocrinology · doi:10.1210/en.2008-0816 · Cited by 1,031
Kurosu, H., Choi, M., Ogawa, Y., Dickson, A. S., Goetz, R., Eliseenkova, A. V., Mohammadi, M., Rosenblatt, K. P., Kliewer, S. A., & Kuro-o, M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704165200 · Cited by 748
The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21
Kharitonenkov, A., Wroblewski, V. J., Koester, A., Chen, Y.-F., Clutinger, C. K., Tigno, X. T., Hansen, B. C., Shanafelt, A. B., & Etgen, G. J. (2007) · Endocrinology · doi:10.1210/en.2006-1168 · Cited by 738
PEGylation of therapeutic proteins
Jevševar, S., Kunstelj, M., & Porekar, V. G. (2010) · Biotechnology Journal · doi:10.1002/biot.200900218 · Cited by 681
Cited by
Sorted by citations
Items 101–122 of 122
Insights into the role of FGF21 in coronary heart disease
Zhang, Q.-Y., & Liu, H. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.136911 · Cited by 4
Du, P., Wang, T., Wang, R., Liu, S., Wang, H., & Yin, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062672 · Cited by 4
Potential role of Akt in the regulation of fibroblast growth factor 21 by berberine
Hirai, T., Wang, W., Murono, N., Iwasa, K., & Inoue, M. (2023) · Journal of Natural Medicines · doi:10.1007/s11418-023-01755-1 · Cited by 4
Process Development and Intensification for a Recombinant Protein Expressed in E.coli
Chen, S., Wellborn, W. B., Cundy, J. T., Mangalathillam, R., Cook, S., Stork, M. J., Martin, J. P., Caparon, M. H., Sobacke, S. E., Srinivasan, S., et al. (2018) · Elsevier eBooks · doi:10.1016/b978-0-08-100623-8.00038-4 · Cited by 4
Rational Design of a Humanized Glucagon‐Like Peptide‐1 Receptor Agonist Antibody
Zhang, Y., Zou, H., Wang, Y., Caballero, D., González, J., Chao, E., Welzel, G., Shen, W., Wang, D., Schultz, P. G., et al. (2014) · Angewandte Chemie · doi:10.1002/ange.201410049 · Cited by 4
Bibliometric analysis of fibroblast growth factor 21 research over the period 2000 to 2021
She, Q.-Y., Li, L., Liu, M.-H., Tan, R.-Y., Zhong, Y.-W., Bao, J., & Xie, J.-D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1011008 · Cited by 9
Self-citationP rocess development of a FGF21 protein–antibody conjugate
Dirksen, A., Davis, K. A., Collins, J. T., Bhattacharya, K., Finneman, J. I., Pepin, E., Ryczek, J., Brown, P. W., Wellborn, W. B., Mangalathillam, R., et al. (2017) · Peptide Science · doi:10.1002/bip.23042 · Cited by 2
Novel FGF21 analogues through structure-based optimization for therapeutic development
Guo, Y., Bao, Y., Chen, Z., Rao, Z., Luo, Y., Ye, S., & Liu, S. (2024) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2024227 · Cited by 2
Li, X. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15793-6.00004-4 · Cited by 2
Zhang, Y., Hu, X., Cao, Z., Zhou, K., Sun, Y., Deng, Y., Xu, S., Nan, Y., Gai, X., Li, M., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148726 · Cited by 1
Yie, J., Mou, Z., & Liu, X. (2026) · Antibody Therapeutics · doi:10.1093/abt/tbag029 · Cited by 1
All about that Amide Bond: The Sixth Chemical Protein Synthesis (CPS) Meeting
Weller, C. E., & Chatterjee, C. (2015) · ChemBioChem · doi:10.1002/cbic.201500473 · Cited by 1
Li, X. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15793-6.00001-9 · Cited by 1
Cold-mediated regulation of systemic retinol transport controls adipose tissue browningPreprint
Fenzl, A., Kulterer, O. C., Spirk, K., Mitulović, G., Marculescu, R., Bilban, M., Baumgartner-Parzer, S. M., Kautzky‐Willer, A., Kenner, L., Plutzky, J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.07.938688 · Cited by 1
Harnessing the Action of Fibroblast Growth Factor21 as a Therapeutic Agent
Brunetti, L., & Kagan, L. (2017) · Current Pharmacology Reports · doi:10.1007/s40495-017-0080-7
The Role Of Crebh In Hepatic Energy Regulation Under Metabolic Stress
Mendez, R. (2015) · Human Biology
Fibroblast growth factor 21 responds to taurocholic acid sodium-induced acute pancreatic injury
Zhang, L., Lin, Y., Ma, X., Xu, F., & Li, P. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.110761
Kim, D. H., & Jeong, Y. T. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02231-y
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
Leung, H.-K., Tan, G.-J., Wong, W., Khamis, F., Zain, S. M., & Chan, W. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.20
Advances in FGF/FGFR Signaling: Implications for Disease and Therapy
Song, M., Liu, X., Xiao, Y., Li, Y., & Zhao, H. (2026) · MedComm · doi:10.1002/mco2.70922
Metadata
- Authors
- Huang, J., Ishino, T., Chen, G., Rolzin, P., Osothprarop, T. F., Retting, K., Li, L., Jin, P., Matin, M. J., Huyghe, B., Talukdar, S., Bradshaw, C. W., Palanki, M., Violand, B. N., Woodnutt, G., Lappe, R. W., Ogilvie, K., & Levin, N.
- Affiliations
- Pfizer (United States) (US)
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2013-08
- Volume
- 346
- Issue
- 2
- Pages
- 270-280
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2029880965
- Cited by
- 121
- References
- 36
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 8 · 2023: 5 · 2022: 9 · 2021: 8 · 2020: 11 · 2019: 7 · 2018: 9 · 2017: 11 · 2016: 9 · 2015: 19 · 2014: 9 · 2013: 3
- FWCI
- 5.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Pharmacology and Experimental Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- FGF21, protein conjugation, long-acting drugs, protein half-life extension, insulin sensitivity, glucose tolerance, obesity, type 2 diabetes, ob/ob mice, db/db mice, hepatic steatosis
- MeSH terms
- Animals, Antibodies, Body Weight, Cysteine, Delayed-Action Preparations, Diabetes Mellitus, Energy Metabolism, Fibroblast Growth Factors, Humans, Hypoglycemic Agents, Immunoglobulin Fab Fragments, Lysine, Macaca fascicularis, Male, Mice, Obese, Recombinant Proteins, Rats, Sprague-Dawley, Molecular Mimicry, 3T3-L1 Cells, Insulin-Secreting Cells, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
